Annovis Bio, Inc. Share Price & Technical Analysis
ANVS · $2.23 (+3.72%)
Healthcare / Biotechnology
$2.23
+3.72%
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury …
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
10% return in May, 21% avg return in past 3 year May month.
-38% return in 2026, 36% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -23% | 0% | -12% | -13% | 10% | – | – | – | – | – | – | – | -38% |
| 25 | -2% | -56% | -21% | 0% | 53% | -4% | 23% | -15% | -9% | 5% | 143% | -30% | 87% |
| 24 | -42% | -27% | 35% | -53% | 20% | -12% | 55% | -10% | -2% | 13% | -29% | -26% | -77% |
| 23 | 20% | -1% | -10% | 9% | -10% | 12% | -2% | -9% | -25% | -31% | 29% | 115% | 97% |
| 22 | -16% | -8% | -5% | -31% | -3% | 23% | 0% | 0% | 21% | -8% | 4% | 1% | -22% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$79.68M
P/E ratio
—
52W high
$5.50
52W low
$1.54
Volume
26,02,302
Beta
1.26
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Annovis Bio, Inc. share price today?
- Annovis Bio, Inc. (ANVS) last traded around $2.23 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ANVS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ANVS. Download the app for real-time alerts.
- How can I analyze Annovis Bio, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.